MedTrace Logo

DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma

NCT03714334 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-04-07

No results posted yet for this study

Summary

Patients with first or second recurrence of GBM will be treated with stereotactic injection of the oncolytic virus DNX-2440.

Conditions

Interventions

DRUG

DNX-2440 injection

DNX-2440 virus will be injected stereotactically

Sponsors & Collaborators

  • DNAtrix, Inc.

    collaborator INDUSTRY

  • Clinica Universidad de Navarra, Universidad de Navarra

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-16
Primary Completion
2023-04-05
Completion
2023-04-05

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03714334 on ClinicalTrials.gov